404 related articles for article (PubMed ID: 19475777)
1. Safety and efficacy of alteplase in the treatment of acute ischemic stroke.
Micieli G; Marcheselli S; Tosi PA
Vasc Health Risk Manag; 2009; 5(1):397-409. PubMed ID: 19475777
[TBL] [Abstract][Full Text] [Related]
2. Treating as early as possible with thrombolysis is crucial, but can we do better in the sub-4.5-hour time window?
Parsons MW
Cerebrovasc Dis; 2011; 31(3):229. PubMed ID: 21178346
[No Abstract] [Full Text] [Related]
3. Thrombolysis at 3-4.5 hours after acute ischemic stroke onset--evidence from the Canadian Alteplase for Stroke Effectiveness Study (CASES) registry.
Shobha N; Buchan AM; Hill MD;
Cerebrovasc Dis; 2011; 31(3):223-8. PubMed ID: 21178345
[TBL] [Abstract][Full Text] [Related]
4. Intravenous thrombolysis for acute ischemic stroke.
Tomsick TA
J Vasc Interv Radiol; 2004 Jan; 15(1 Pt 2):S67-76. PubMed ID: 15106579
[TBL] [Abstract][Full Text] [Related]
5. Local intra-arterial thrombolysis with urokinase for acute ischemic stroke before and after the approval of intravenous tissue plasminogen activator treatment in Taiwan.
Yang FC; Lin CC; Hsueh CJ; Lee JT; Hsu CH; Lee KW; Peng GS
Ann Vasc Surg; 2010 Nov; 24(8):1117-24. PubMed ID: 21035704
[TBL] [Abstract][Full Text] [Related]
6. Thrombolysis for acute ischemic stroke.
Hajjar K; Kerr DM; Lees KR
J Vasc Surg; 2011 Sep; 54(3):901-7. PubMed ID: 21889708
[TBL] [Abstract][Full Text] [Related]
7. Comparison of combined venous and arterial thrombolysis with primary arterial therapy using recombinant tissue plasminogen activator in acute ischemic stroke.
Wolfe T; Suarez JI; Tarr RW; Welter E; Landis D; Sunshine JL; Zaidat OO
J Stroke Cerebrovasc Dis; 2008; 17(3):121-8. PubMed ID: 18436152
[TBL] [Abstract][Full Text] [Related]
8. Utilization of Intravenous Tissue Plasminogen Activator and Reasons for Nonuse in Acute Ischemic Stroke in Saudi Arabia.
Al Khathaami AM; Al Bdah B; Tarawneh M; Alskaini M; Alotaibi F; Alshalan A; Almuhraj M; Aldaham D; Alotaibi N
J Stroke Cerebrovasc Dis; 2020 May; 29(5):104761. PubMed ID: 32173225
[TBL] [Abstract][Full Text] [Related]
9. Safety of intravenous thrombolysis in ischemic stroke caused by left atrial myxoma.
Acampa M; Tassi R; Guideri F; Marotta G; Monti L; Capannini G; Cerase A; Martini G
Curr Drug Saf; 2011 Nov; 6(5):343-5. PubMed ID: 22424543
[TBL] [Abstract][Full Text] [Related]
10. Acetylsalicylic acid pretreatment, concomitant heparin therapy and the risk of early intracranial hemorrhage following systemic thrombolysis for acute ischemic stroke.
Schmülling S; Rudolf J; Strotmann-Tack T; Grond M; Schneweis S; Sobesky J; Thiel A; Heiss WD
Cerebrovasc Dis; 2003; 16(3):183-90. PubMed ID: 12865603
[TBL] [Abstract][Full Text] [Related]
11. Safety of standard-dose (.9-mg/kg) alteplase intravenous thrombolysis for acute ischemic stroke in Afro-Caribbeans, French West Indies.
Chausson N; Olindo S; Joux J; Saint-Vil M; Aveillan M; Smadja D
J Stroke Cerebrovasc Dis; 2014 Aug; 23(7):1776-80. PubMed ID: 24957315
[TBL] [Abstract][Full Text] [Related]
12. Low-Dose Tissue Plasminogen Activator in Acute Ischemic Stroke: A Systematic Review and Meta-Analysis.
Cheng JW; Zhang XJ; Cheng LS; Li GY; Zhang LJ; Ji KX; Zhao Q; Bai Y
J Stroke Cerebrovasc Dis; 2018 Feb; 27(2):381-390. PubMed ID: 29111341
[TBL] [Abstract][Full Text] [Related]
13. Renal impairment reduces the efficacy of thrombolytic therapy in acute ischemic stroke.
Power A; Epstein D; Cohen D; Bathula R; Devine J; Kar A; Taube D; Duncan N; Ames D
Cerebrovasc Dis; 2013; 35(1):45-52. PubMed ID: 23428996
[TBL] [Abstract][Full Text] [Related]
14. Efficacy of Tirofiban Administered at Different Time Points after Intravenous Thrombolytic Therapy with Alteplase in Patients with Acute Ischemic Stroke.
Liu J; Shi Q; Sun Y; He J; Yang B; Zhang C; Guo R
J Stroke Cerebrovasc Dis; 2019 Apr; 28(4):1126-1132. PubMed ID: 30655038
[TBL] [Abstract][Full Text] [Related]
15. Role of tissue plasminogen activator in acute ischemic stroke.
Hatcher MA; Starr JA
Ann Pharmacother; 2011 Mar; 45(3):364-71. PubMed ID: 21386027
[TBL] [Abstract][Full Text] [Related]
16. Renal Dysfunction Associated with Symptomatic Intracranial Hemorrhage after Intravenous Thrombolysis.
Zhu J; Shen X; Han C; Mei C; Zhou Y; Wang H; Kong Y; Jiang Y; Fang Q; Cai X
J Stroke Cerebrovasc Dis; 2019 Nov; 28(11):104363. PubMed ID: 31501038
[TBL] [Abstract][Full Text] [Related]
17. Thrombolysis with alteplase 3 to 4.5 hours after acute ischemic stroke.
Hacke W; Kaste M; Bluhmki E; Brozman M; Dávalos A; Guidetti D; Larrue V; Lees KR; Medeghri Z; Machnig T; Schneider D; von Kummer R; Wahlgren N; Toni D;
N Engl J Med; 2008 Sep; 359(13):1317-29. PubMed ID: 18815396
[TBL] [Abstract][Full Text] [Related]
18. Thrombolytic Treatment for Ischaemic Stroke: Could the Crisis of Confidence Have Been Avoided by Better Analysis of Trial Data?
Barer D; Berge E
Drugs Aging; 2017 Feb; 34(2):79-88. PubMed ID: 28120326
[TBL] [Abstract][Full Text] [Related]
19. Generalized Safety and Efficacy of Simplified Intravenous Thrombolysis Treatment (SMART) Criteria in Acute Ischemic Stroke: The MULTI SMART Study.
Sørensen SB; Barazangi N; Chen C; Wong C; Grosvenor D; Rose J; Bedenk A; Morrow M; McDermott D; Hove JD; Tong DC
J Stroke Cerebrovasc Dis; 2016 May; 25(5):1110-1118. PubMed ID: 26897101
[TBL] [Abstract][Full Text] [Related]
20. Thrombolysis with alteplase 4.5-6 hours after acute ischemic stroke.
Zhang B; Sun XJ; Ju CH
Eur Neurol; 2011; 65(3):170-4. PubMed ID: 21372577
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
